First Tracks Biotherapeutics, Inc.
firsttracksbio.comFirst Tracks Biotherapeutics Inc (NASDAQ: TRAX) is a clinical-stage biotherapeutics company that develops antibody therapeutics targeting autoimmune and inflammatory diseases. The company generates no product revenue; it operates entirely on research and development spending funded through its capital base, with interest income from short-term and long-term investments as its only recurring income line (as of Q1 2026 10-Q, filed 2026-05-14). First Tracks was spun off from AnaptysBio, Inc. and operates as an independent public company. Its pipeline centers on two antibody programs: rosnilimab, a PD-1 agonist antibody evaluated in rheumatoid arthritis through Phase 2 (End-of-Phase 2 meeting with FDA completed Q1 2026), and ANB101, a BDCA2 modulator antibody targeting plasmacytoid dendritic cells for diseases including systemic lupus erythematosus, with a Phase 1 clinical trial in healthy volunteers initiated March 2025. The company conducts some preclinical work internally and relies on contract research organizations and contract manufacturing organizations for in vivo studies, drug manufacturing, and clinical execution.
Products & Services
Rosnilimab: PD-1 agonist antibody in development for rheumatoid arthritis; Phase 2 data through Week 28 reported, End-of-Phase 2 meeting with FDA completed Q1 2026. ANB101: BDCA2 modulator antibody targeting plasmacytoid dendritic cells to inhibit interferon secretion; Phase 1 clinical trial in healthy volunteers initiated March 2025, ongoing as of filing date 2026-05-14. Both candidates target autoimmune and inflammatory diseases.
Revenue Model
Pre-revenue clinical-stage company. No product sales as of Q1 2026. Operating expenses consist of research and development costs and general and administrative expenses. Income is limited to interest earned on short-term and long-term investments. The company operates at a net loss.
Customers & Markets
No commercial customers as of Q1 2026. End markets are autoimmune and inflammatory disease patients, specifically rheumatoid arthritis (rosnilimab) and systemic lupus erythematosus and related inflammatory conditions (ANB101). Clinical trial participants are the current subject population.
Geographic Exposure
U.S.-based company subject to FDA regulatory oversight. Geographic revenue exposure not applicable given pre-revenue status. No geographic segment disclosures in the filing excerpts.
Source: SEC 10-Q, filed 2026-05-14
Financial Snapshot
Loading...
